Skip to main content

Table 3 Distribution of C4 polymorphisms in Graves' disease patients with or without myxedema

From: Association between copy number variation of complement component C4 and Graves' disease

Variations

Myxedema

P value, individuala

[OR (95%CI), individual]c

P valueb

OR (95%CI)d

 

No, N (%)

Yes, N (%)

   

C4 CNV

     

4

265 (50.5)

48 (49.0)

0.826

 

(Reference)

< 4

100 (19.0)

34 (34.7)

0.001 [1.884 (0.538-6.597)]

4.900 × 10-4

1.714 (0.447-6.575)

> 4

160 (30.5)

16 (16.3)

0.005 [0.617 (0.166-2.289)]

 

0.761 (0.186-3.122)

C4A CNV

     

2

336 (64.0)

58 (59.2)

0.364

 

(Reference)

< 2

57 (10.9)

22 (22.5)

0.003 [0.627 (0.164-2.404)]

0.008

0.511 (0.122-2.134)

> 2

132 (25.1)

18 (18.4)

0.159

 

0.496 (0.117-2.106)

C4B CNV

     

2

317 (60.4)

59 (60.2)

1

 

(Reference)

< 2

115 (21.9)

28 (28.6)

0.152

0.168

1.163 (0.298-4.542)

> 2

93 (17.7)

11 (11.2)

0.072

 

0.552 (0.125-2.443)

C4 polymorphisms

     

A2B2

217 (41.3)

36 (36.7)

0.434

0.050

(Reference)

A2B1

63 (12.0)

15 (15.3)

0.405

 

1.895 (0.307-11.710)

A3B2

58 (11.0)

6 (6.1)

0.202

 

1.371 (0.163-11.522)

A2B3

41 (7.8)

3 (3.1)

0.130

 

0.558 (0.029-10.789)

A3B1

26 (5.0)

6 (6.1)

0.619

 

0.333 (0.032-3.499)

A1B2

23 (4.4)

11 (11.2)

0.013 [1.094 (0.137-8.709)]

 

1.009 (0.103-9.841)

Other

97 (18.5)

21 (21.4)

  

0.735 (0.163-3.310)

  1. Abbreviations: GD, Graves' disease; GO, Graves' ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.
  2. aIndividual C4 CNVs and polymorphisms between GD patients with or without myxedema were evaluated by Fisher's exact test using 2 × 2 contingency tables.
  3. b CNV of C4, C4A and C4B between GD patients with or without myxedema were evaluated by Fisher's exact test using 3 × 2 contingency tables.C4 polymorphisms between GD patients with or without myxedema were evaluated by Fisher's exact test using 7 × 2 contingency tables. The p value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).
  4. cORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, GO and vitiligo.
  5. dORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, GO and vitiligo.